Ignite Creation Date:
2025-12-24 @ 10:34 PM
Ignite Modification Date:
2025-12-25 @ 8:06 PM
Study NCT ID:
NCT05365035
Status:
RECRUITING
Last Update Posted:
2025-10-22
First Post:
2022-04-26
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
A Phase II Study of Cladribine and Low Dose Cytarabine in Combination With Venetoclax, Alternating With Azacitidine and Venetoclax, in Patients With Higher-risk Myeloproliferative Chronic Myelomonocytic Leukemia or Higher-risk Myelodysplastic Syndromes With Excess Blasts
Sponsor:
M.D. Anderson Cancer Center
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2022-09-23
Start Date Type:
ACTUAL
Primary Completion Date:
2025-12-01
Primary Completion Date Type:
ESTIMATED
Completion Date:
2025-12-01
Completion Date Type:
ESTIMATED
First Submit Date:
2022-04-26
First Submit QC Date:
None
Study First Post Date:
2022-05-06
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-10-20
Last Update Post Date:
2025-10-22
Last Update Post Date Type:
ESTIMATED